Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or

Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial shows.

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to general weight loss. Is this a real concern, and if so, how can a person maintain their muscle mass on GLP-1 drugs?

Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.

The Biden administration called for Medicare and Medicaid to cover popular drugs that help people lose weight but are not affordable for many Americans who might benefit from them. NBC News' Stephanie Gosk reports.